Key Highlights
● Arbutus received US$178.4 million on 8 July 2026 from the Moderna settlement.
● A further US$1.3 billion from Moderna depends on an appellate ruling.
● Cash and securities were US$92.6 million at 30 June 2026, before the July receipt.
● Management intends to return up to about US$230 million through share repurchases.
Arbutus Biopharma Corporation (NASDAQ:ABUS) reported second-quarter 2026 results on 12 August 2026. All figures are in US dollars unless stated.
The headline financial picture is of a small clinical-stage business whose balance sheet has been transformed by litigation. Revenue for the quarter ended 30 June 2026 was US$1.0 million, against US$10.7 million in the second quarter of 2025, which had included US$9.6 million of deferred revenue recognised when a partnership with Qilu concluded. The net loss was US$5.1 million, or US$0.03 per share, compared with net income of US$2.5 million, or US$0.01 per share, a year earlier.
Costs and cash
Research and development expense fell to US$2.9 million from US$5.5 million, which the company attributes mainly to workforce reductions, the end of in-house research and lower clinical trial costs. General and administrative expense rose to US$3.9 million from US$3.3 million, mainly because of higher share-based compensation. No restructuring costs were recorded in the quarter.
Cash, cash equivalents and marketable securities were US$92.6 million at 30 June 2026, compared with US$91.5 million at the end of 2025. Over six months the business used US$14.1 million in operations, including one-off restructuring payments, and received US$14.7 million from stock option exercises. At period-end there were 197.6 million common shares outstanding, plus 8.6 million options and unvested restricted stock units.
The Moderna settlement
The most significant item is a settlement agreement dated 3 March 2026, reached with Genevant, that resolved global patent litigation with Moderna. According to the release, Moderna paid a noncontingent US$950 million in July 2026, of which Arbutus received US$178.4 million on 8 July 2026. Because that receipt arrived after the quarter closed, it is not in the 30 June cash figure.
A further contingent payment of US$1.3 billion from Moderna depends on an appellate ruling, and the release gives no timing for that decision. The company also disclosed that three international patent suits were filed in July 2026 against Pfizer and BioNTech across 21 countries, and that it owns roughly 16% of Genevant's common equity.
Clinical programmes
Imdusiran, the company's candidate for chronic hepatitis B, received Fast Track designation from the US Food and Drug Administration in April 2026. In May 2026 the company reached alignment with the regulator on the design and safety parameters of a proposed Phase 2b trial and said it would finalise the protocol using that feedback. AB-101, an oral PD-L1 inhibitor, is listed as a programme without any update.
Trial timing was not specified. A Form 10-Q was listed for filing on 12 August 2026, containing accounting detail.
Litigation Proceeds, Buybacks and the Appeal Outcome Drive the Story
Management says it intends to begin returning capital in the third quarter of 2026, with repurchases of up to about US$230 million of common shares. The release is explicit that this is subject to board approval and is not guaranteed. A material dividend from Genevant is also expected in the third quarter. These are forward-looking statements by management, not completed events.
The equity story now depends less on the pipeline and more on the size and timing of litigation proceeds, the outcome of the appeal and how capital is allocated between buybacks and the hepatitis B trial.






Please wait processing your request...